InVitae Stock Price, News & Analysis (NYSE:NVTA)

$8.45 -0.19 (-2.20 %)
(As of 12/12/2017 01:16 AM ET)
Previous Close$8.64
Today's Range$8.41 - $8.75
52-Week Range$2.60 - $8.95
Volume195,053 shs
Average Volume134,091 shs
Market Capitalization$457.45 million
P/E RatioN/A
Dividend YieldN/A
Beta1.3

About InVitae (NYSE:NVTA)

InVitae logoInvitae Corporation utilizes an integrated portfolio of laboratory processes, software tools and informatics capabilities to process deoxyribonucleic acid (DNA)-containing samples, analyze information about patient-specific genetic variation and generate test reports for clinicians and their patients. As of December 31, 2016, the Company's products consisted of assays totaling over 1,100 genes that could be used for multiple indications, including hereditary cancer, neurological disorders, cardiovascular disorders, pediatric disorders and other hereditary conditions. The Company offers panels for a range of hereditary conditions in cancer, cardiology, neuromuscular, pediatric and rare diseases. The Company focuses on genetic testing, genome network and genome management. The Company offers full gene sequencing and deletion/duplication analysis as a standard for all of its tests. The Company holds interests in AltaVoice, a patient-centered data company.

Receive NVTA News and Ratings via Email

Sign-up to receive the latest news and ratings for NVTA and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Diagnostics & Testing
Sub-IndustryN/A
SectorMedical
SymbolNYSE:NVTA
CUSIPN/A
Phone415-374-7782

Debt

Debt-to-Equity Ratio0.33%
Current Ratio2.61%
Quick Ratio2.61%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$25.05 million
Price / Sales17.86
Cash FlowN/A
Price / CashN/A
Book Value$2.41 per share
Price / Book3.51

Profitability

Trailing EPS($2.56)
Net Income$-100,250,000.00
Net Margins-206.95%
Return on Equity-115.25%
Return on Assets-67.79%

Miscellaneous

Employees332
Outstanding Shares52,940,000

InVitae (NYSE:NVTA) Frequently Asked Questions

What is InVitae's stock symbol?

InVitae trades on the New York Stock Exchange (NYSE) under the ticker symbol "NVTA."

How were InVitae's earnings last quarter?

InVitae Corp (NYSE:NVTA) announced its earnings results on Monday, August, 8th. The medical research company reported ($0.77) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.76) by $0.01. The medical research company had revenue of $5.60 million for the quarter, compared to analysts' expectations of $5.81 million. InVitae had a negative return on equity of 115.25% and a negative net margin of 206.95%. The business's revenue was up 211.1% on a year-over-year basis. During the same quarter last year, the business posted ($0.76) earnings per share. View InVitae's Earnings History.

When will InVitae make its next earnings announcement?

InVitae is scheduled to release their next quarterly earnings announcement on Monday, February, 12th 2018. View Earnings Estimates for InVitae.

Where is InVitae's stock going? Where will InVitae's stock price be in 2017?

3 analysts have issued 12-month price targets for InVitae's shares. Their forecasts range from $12.00 to $16.00. On average, they expect InVitae's stock price to reach $14.33 in the next year. View Analyst Ratings for InVitae.

Who are some of InVitae's key competitors?

Who are InVitae's key executives?

InVitae's management team includes the folowing people:

  • Randal W. Scott Ph.D., Executive Chairman of the Board (Age 59)
  • Sean E. George Ph.D., President, Chief Executive Officer, Co-Founder, Director (Age 43)
  • Shelly D Guyer, Chief Financial Officer (Age 56)
  • Lee Bendekgey J.D., Chief Operating Officer, General Counsel, Secretary (Age 59)
  • Robert L. Nussbaum M.D., Chief Medical Officer (Age 67)
  • Christine M. Gorjanc, Lead Independent Director (Age 60)
  • Eric Aguiar M.D., Independent Director (Age 55)
  • Geoffrey S. Crouse, Independent Director (Age 46)

When did InVitae IPO?

(NVTA) raised $76 million in an initial public offering on Thursday, February 12th 2015. The company issued 5,400,000 shares at $13.00-$15.00 per share. J.P. Morgan acted as the underwriter for the IPO and Cowen and Company and Leerink Partners were co-managers.

Who owns InVitae stock?

InVitae's stock is owned by many different of institutional and retail investors. Top institutional investors include Perceptive Advisors LLC (3.75%), Orbimed Advisors LLC (3.02%), Bank of New York Mellon Corp (0.35%), Allianz Asset Management GmbH (0.34%), Schwab Charles Investment Management Inc. (0.32%) and Private Wealth Partners LLC (0.20%). Company insiders that own InVitae stock include Bros Advisors Lp Baker, E Lee Bendekgey, Geoffrey Crouse, Katherine Stueland, Lisa Alderson, Patty Dumond, Randal W Scott, Robert L Nussbaum, Sean E George and Thomas Brida. View Institutional Ownership Trends for InVitae.

Who sold InVitae stock? Who is selling InVitae stock?

InVitae's stock was sold by a variety of institutional investors in the last quarter, including Cubist Systematic Strategies LLC and California State Teachers Retirement System. Company insiders that have sold InVitae company stock in the last year include E Lee Bendekgey, Katherine Stueland, Patty Dumond, Robert L Nussbaum and Thomas Brida. View Insider Buying and Selling for InVitae.

Who bought InVitae stock? Who is buying InVitae stock?

InVitae's stock was bought by a variety of institutional investors in the last quarter, including Perceptive Advisors LLC, Orbimed Advisors LLC, Private Wealth Partners LLC, Allianz Asset Management GmbH, Schwab Charles Investment Management Inc., Fox Run Management L.L.C., OxFORD Asset Management LLP and CAPROCK Group Inc.. Company insiders that have bought InVitae stock in the last two years include Bros Advisors Lp Baker, Geoffrey Crouse, Randal W Scott and Sean E George. View Insider Buying and Selling for InVitae.

How do I buy InVitae stock?

Shares of InVitae can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is InVitae's stock price today?

One share of InVitae stock can currently be purchased for approximately $8.45.

How big of a company is InVitae?

InVitae has a market capitalization of $457.45 million and generates $25.05 million in revenue each year. The medical research company earns $-100,250,000.00 in net income (profit) each year or ($2.56) on an earnings per share basis. InVitae employs 332 workers across the globe.

How can I contact InVitae?

InVitae's mailing address is 1400 16th Street, SAN FRANCISCO CA, 94103. The medical research company can be reached via phone at 415-374-7782 or via email at [email protected]


MarketBeat Community Rating for InVitae (NVTA)

Community Ranking:  1.9 out of 5 (star)
Outperform Votes:  93 (Vote Outperform)
Underperform Votes:  151 (Vote Underperform)
Total Votes:  244
MarketBeat's community ratings are surveys of what our community members think about InVitae and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

InVitae (NYSE:NVTA) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $14.33$14.33$14.33$14.00
Price Target Upside: 58.03% upside58.03% upside55.46% upside26.58% upside

InVitae (NYSE:NVTA) Consensus Price Target History

Price Target History for InVitae (NYSE:NVTA)

InVitae (NYSE:NVTA) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/7/2017Leerink SwannLower Price TargetOutperform$14.00 -> $12.00N/AView Rating Details
8/9/2017J P Morgan Chase & CoReiterated RatingOverweight$14.00 -> $15.00LowView Rating Details
4/3/2017BenchmarkReiterated RatingBuy -> Buy$11.00 -> $16.00HighView Rating Details
(Data available from 12/12/2015 forward)

Earnings

InVitae (NYSE:NVTA) Earnings History and Estimates Chart

Earnings by Quarter for InVitae (NYSE:NVTA)

InVitae (NYSE NVTA) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/12/2018($0.55)N/AView Earnings Details
8/7/20176/30/2017($0.64)($0.66)$13.31 million$14.34 millionViewListenView Earnings Details
5/9/2017Q1 2017($0.68)($0.64)$10.90 million$10.34 millionViewListenView Earnings Details
2/13/2017Q416($0.73)($0.69)$8.82 million$9.20 millionViewN/AView Earnings Details
11/7/2016Q316($0.72)($0.77)$7.50 million$6.30 millionViewListenView Earnings Details
8/8/2016Q216($0.76)($0.77)$5.81 million$5.60 millionViewN/AView Earnings Details
5/9/2016Q116($0.76)($0.80)$4.38 million$4.00 millionViewN/AView Earnings Details
2/9/2016Q415($0.72)($0.76)$2.92 million$3.20 millionViewN/AView Earnings Details
11/5/2015Q315($0.70)($0.71)$2.55 million$2.19 millionViewN/AView Earnings Details
8/6/2015Q215($0.55)($0.76)$1.67 million$1.80 millionViewN/AView Earnings Details
5/12/2015Q115($0.51)($1.09)$1.07 million$1.23 millionViewListenView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

InVitae (NYSE:NVTA) Earnings Estimates

Current Year EPS Consensus Estimate: $-2.45 EPS
Next Year EPS Consensus Estimate: $-1.7 EPS

Dividends

Dividend History for InVitae (NYSE:NVTA)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

InVitae (NYSE NVTA) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 9.90%
Institutional Ownership Percentage: 66.52%
Insider Trades by Quarter for InVitae (NYSE:NVTA)
Insider Trades by Quarter for InVitae (NYSE:NVTA)

InVitae (NYSE NVTA) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
10/10/2017Patty DumondVPSell2,497$10.00$24,970.00View SEC Filing  
10/9/2017Patty DumondVPSell1,882$10.00$18,820.00View SEC Filing  
9/12/2017Katherine StuelandInsiderSell612$9.40$5,752.80View SEC Filing  
2/16/2017Thomas BridaGeneral CounselSell766$9.69$7,422.54View SEC Filing  
2/15/2017E Lee BendekgeyCFOSell2,098$9.59$20,119.82View SEC Filing  
2/15/2017Patty DumondVPSell1,264$9.55$12,071.20View SEC Filing  
2/15/2017Robert L NussbaumInsiderSell1,686$9.53$16,067.58View SEC Filing  
2/15/2017Thomas BridaGeneral CounselSell794$9.54$7,574.76View SEC Filing  
11/22/2016Randal W ScottChairmanBuy66,666$6.00$399,996.00View SEC Filing  
11/18/2016Geoffrey CrouseDirectorBuy15,000$6.25$93,750.00View SEC Filing  
11/17/2016Bros. Advisors Lp BakerMajor ShareholderBuy733,333$6.00$4,399,998.00View SEC Filing  
9/16/2016Patty DumondVPSell1,000$8.00$8,000.00View SEC Filing  
8/15/2016Patty DumondVPSell1,000$8.81$8,810.00View SEC Filing  
7/14/2016Patty DumondVPSell1,000$8.79$8,790.00View SEC Filing  
6/16/2016Patty DumondVPSell1,000$8.00$8,000.00View SEC Filing  
5/17/2016Patty DumondVPSell3,221$8.47$27,281.87View SEC Filing  
4/14/2016Patty DumondVPSell1,000$10.50$10,500.00View SEC Filing  
2/22/2016Lisa AldersonInsiderSell7,500$7.64$57,300.00View SEC Filing  
2/11/2016Sean E GeorgeCOOBuy16,950$6.16$104,412.00View SEC Filing  
2/18/2015James E FlynnInsiderBuy175,000$16.00$2,800,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

InVitae (NYSE NVTA) News Headlines

Source:
DateHeadline
InVitae Corp (NVTA) Receives Consensus Rating of "Hold" from BrokeragesInVitae Corp (NVTA) Receives Consensus Rating of "Hold" from Brokerages
www.americanbankingnews.com - December 11 at 6:46 PM
ETFs with exposure to Invitae Corp. : December 11, 2017ETFs with exposure to Invitae Corp. : December 11, 2017
finance.yahoo.com - December 11 at 4:41 PM
InVitae Corp (NVTA) Expected to Announce Quarterly Sales of $25.87 MillionInVitae Corp (NVTA) Expected to Announce Quarterly Sales of $25.87 Million
www.americanbankingnews.com - December 11 at 2:56 PM
Vermillion (VRML) & InVitae (NVTA) Critical ComparisonVermillion (VRML) & InVitae (NVTA) Critical Comparison
www.americanbankingnews.com - December 10 at 3:30 PM
InVitae Corp (NVTA) Expected to Announce Earnings of -$0.55 Per ShareInVitae Corp (NVTA) Expected to Announce Earnings of -$0.55 Per Share
www.americanbankingnews.com - December 9 at 8:04 AM
Financial Survey: Veracyte (VCYT) versus InVitae (NVTA)Financial Survey: Veracyte (VCYT) versus InVitae (NVTA)
www.americanbankingnews.com - December 3 at 9:48 PM
Invitae Corp. :NVTA-US: Earnings Analysis: Q3, 2017 By the Numbers : November 30, 2017Invitae Corp. :NVTA-US: Earnings Analysis: Q3, 2017 By the Numbers : November 30, 2017
finance.yahoo.com - November 30 at 11:01 AM
Comparing Digiliti Money (DGLT) & InVitae (NVTA)Comparing Digiliti Money (DGLT) & InVitae (NVTA)
www.americanbankingnews.com - November 29 at 9:44 PM
Contrasting InVitae (NVTA) and CareDx (CDNA)Contrasting InVitae (NVTA) and CareDx (CDNA)
www.americanbankingnews.com - November 27 at 10:10 AM
Invitae Corporation (NVTA) Rating Lowered to Strong Sell at BidaskClubInvitae Corporation (NVTA) Rating Lowered to Strong Sell at BidaskClub
www.americanbankingnews.com - November 25 at 12:50 AM
$25.87 Million in Sales Expected for Invitae Corporation (NVTA) This Quarter$25.87 Million in Sales Expected for Invitae Corporation (NVTA) This Quarter
www.americanbankingnews.com - November 23 at 8:58 AM
Critical Analysis: CareDx (CDNA) and Invitae Corporation (NVTA)Critical Analysis: CareDx (CDNA) and Invitae Corporation (NVTA)
www.americanbankingnews.com - November 22 at 1:23 PM
-$0.55 EPS Expected for Invitae Corporation (NVTA) This Quarter-$0.55 EPS Expected for Invitae Corporation (NVTA) This Quarter
www.americanbankingnews.com - November 21 at 9:24 AM
Lion Biotechnologies (IOVA) & Invitae Corporation (NVTA) Critical ReviewLion Biotechnologies (IOVA) & Invitae Corporation (NVTA) Critical Review
www.americanbankingnews.com - November 18 at 1:30 PM
Invitae Corporation (NVTA) Given Consensus Rating of "Hold" by BrokeragesInvitae Corporation (NVTA) Given Consensus Rating of "Hold" by Brokerages
www.americanbankingnews.com - November 16 at 2:10 PM
Invitae reports 1Q lossInvitae reports 1Q loss
marketbeat.com - May 8 at 4:34 PM
Invitae Expands Test Menu for Proactive Genetic Testing in Healthy AdultsInvitae Expands Test Menu for Proactive Genetic Testing in Healthy Adults
us.rd.yahoo.com - March 23 at 7:28 PM
Invitae announces expansion of its genetic testing offering to include unique test for Spinal Muscular Atrophy (SMA) during the 2017 ACMG Annual Clinical Genetics MeetingInvitae announces expansion of its genetic testing offering to include unique test for Spinal Muscular Atrophy (SMA) during the 2017 ACMG Annual Clinical Genetics Meeting
us.rd.yahoo.com - March 22 at 9:10 AM
INVITAE CORP Files SEC form 10-K, Annual ReportINVITAE CORP Files SEC form 10-K, Annual Report
biz.yahoo.com - March 16 at 7:40 PM
Get Ready: Biotech Is Ready To Break OutGet Ready: Biotech Is Ready To Break Out
seekingalpha.com - February 28 at 10:35 AM
18 Biggest Mid-Day Gainers For Tuesday | Benzinga - Benzinga18 Biggest Mid-Day Gainers For Tuesday | Benzinga - Benzinga
www.benzinga.com - February 14 at 10:12 PM
Q4 2016 Invitae Corp Earnings Release - Time Not SuppliedQ4 2016 Invitae Corp Earnings Release - Time Not Supplied
biz.yahoo.com - February 13 at 9:39 AM
Form 8-K Invitae Corp For: Jan 06 - StreetInsider.com - StreetInsider.comForm 8-K Invitae Corp For: Jan 06 - StreetInsider.com - StreetInsider.com
www.streetinsider.com - January 13 at 12:37 AM
INVITAE CORP Files SEC form 8-K, Change in Directors or Principal Officers, Other Events, Financial Statements and ExINVITAE CORP Files SEC form 8-K, Change in Directors or Principal Officers, Other Events, Financial Statements and Ex
biz.yahoo.com - January 9 at 7:38 PM
7:01 am Invitae acquires privately owned AltaVoice; financial details not disclosed7:01 am Invitae acquires privately owned AltaVoice; financial details not disclosed
us.rd.yahoo.com - January 7 at 5:42 AM
InVitae (NVTA) Says it Met Annual Volume Guidance, Sees Doubling in 2017 - StreetInsider.comInVitae (NVTA) Says it Met Annual Volume Guidance, Sees Doubling in 2017 - StreetInsider.com
www.streetinsider.com - January 6 at 7:39 PM
INVITAE CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Completion of Acquisition or DispositionINVITAE CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition
biz.yahoo.com - January 6 at 7:39 PM
InVitae Execs Talk Genetics And Growth - BenzingaInVitae Execs Talk Genetics And Growth - Benzinga
www.benzinga.com - December 18 at 7:12 PM

SEC Filings

InVitae (NYSE:NVTA) SEC Filings

DateFilerForm TypeView
12/01/2017
4:04 PM
InVitae (Subject)
Park West Asset Management LLC (Filed by)
Form SC 13G
View Filing

Social Media

Financials

InVitae (NYSE:NVTA) Income Statement, Balance Sheet and Cash Flow Statement

Chart

InVitae (NYSE NVTA) Stock Chart for Tuesday, December, 12, 2017

Loading chart…

This page was last updated on 12/12/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.